Loading...
Loading...
- CVS Health Corporation's CVS Q3 sales increased 10% Y/Y to $73.79 billion, beating the consensus of $70.49 billion, helped by filling more prescriptions and giving more Covid-19 vaccines.
- Adjusted operating income increased 12.5% to $4.07 billion primarily due to the administration of COVID-19 vaccinations, diagnostic testing, and increased front store volume and growth in specialty pharmacy.
- CVS administered more than 8 million COVID-19 tests and more than 11 million COVID-19 vaccines nationwide in Q3.
- Prescriptions filled increased 8.0% Y/Y, primarily driven by COVID-19 vaccinations.
- CVS said its medical benefit ratio (MBR), or the percentage of premiums paid for medical services, rose to 85.8% from 84%. A lower MBR is better for health insurers as it signals a tight rein on medical costs.
- Adjusted EPS increased 18.7% to $1.97, beating the consensus of $1.78.
- FY21 Outlook: CVS Health raised the adjusted EPS outlook to $7.90 - $8.00 from $7.70 - $7.80 (consensus $7.79).
- The Company also raised FY21 cash flow from operations guidance to $13.0 billion - $13.5 billion from $12.5 billion - $13.0 billion.
- Price Action: CVS shares traded lower at 90.31 premarket on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in